["Medication, Active": "Chemotherapy for Advanced Cancer"]
Performance/Reporting Period
2023
Value Set Description from VSAC
Clinical Focus: This value set contains RxNORM codes associated with chemotherapy agents commonly used to treat patients with advanced stages of cancer.
Data Element Scope: This would use the Medication QDM category.
Inclusion Criteria: The following generic, prescribable chemotherapy agents are included in this value set: altretamine, arsenic trioxide, asparaginase, azacytidine, belinostat, bendamustine, bexarotene, bleomycin, busulfan, cabazitaxel, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, cytarabine liposome, dacarbazine, dactinomycin, daunorubicin, decitabine, docetaxel, doxorubicin, epirubicin, eribulin, estramustine, etoposide, floxuridine, fludarabine, fluorouracil, gemcitabine, hydroxyurea, idarubicin, ifosfamide, irinotecan, ixabepilone, lomustine, mechlorethamine, melphalan, mercaptopurine, methotrexate, mitomycin, mitotane, mitoxantrone, nelarabine, omacetaxine, oxaliplatin, paclitaxel, pegaspargase, pemetrexed, pentostatin, pralatrexate, procarbazine, ruxolitinib, streptozocin, temozolomide, teniposide, thioguanine, thiotepa, topotecan, trabectedin, vinblastine, vincristine.
Exclusion Criteria: Chemotherapy agents not listed above are excluded from this value set, including brand name drugs or brand name drug packs.
Data Element Scope: This would use the Medication QDM category.
Inclusion Criteria: The following generic, prescribable chemotherapy agents are included in this value set: altretamine, arsenic trioxide, asparaginase, azacytidine, belinostat, bendamustine, bexarotene, bleomycin, busulfan, cabazitaxel, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, cytarabine liposome, dacarbazine, dactinomycin, daunorubicin, decitabine, docetaxel, doxorubicin, epirubicin, eribulin, estramustine, etoposide, floxuridine, fludarabine, fluorouracil, gemcitabine, hydroxyurea, idarubicin, ifosfamide, irinotecan, ixabepilone, lomustine, mechlorethamine, melphalan, mercaptopurine, methotrexate, mitomycin, mitotane, mitoxantrone, nelarabine, omacetaxine, oxaliplatin, paclitaxel, pegaspargase, pemetrexed, pentostatin, pralatrexate, procarbazine, ruxolitinib, streptozocin, temozolomide, teniposide, thioguanine, thiotepa, topotecan, trabectedin, vinblastine, vincristine.
Exclusion Criteria: Chemotherapy agents not listed above are excluded from this value set, including brand name drugs or brand name drug packs.
Constrained to codes in the Medication, Active: Chemotherapy for Advanced Cancer value set (2.16.840.1.113883.3.7643.3.1048)
QDM Datatype and Definition
"Medication, Active"
Data elements that meet criteria using this datatype should document that the medication indicated by the QDM category and its corresponding value set is being taken by the patient. Keep in mind that when this datatype is used with timing relationships, the criterion is looking for a medication being taken for the time frame indicated by the timing relationships.
Timing:
- relevant dateTime references the time the medication is active on the medication record if it was given or taken at a single point in time.
- relevantPeriod references a start and stop time for an active medication on the medication record that is given or taken over a time interval:
- The relevantPeriod addresses:
- startTime = when the medication is first known to be used (generally the time of entry on the medication list).
- stopTime = when the medication is no longer active.
eCQMs using this data element:
Last Updated: Jan 15, 2024